A Ubiquinone-Reactive Pt(IV) Prodrug Perturbs Mitochondrial Metabolism for Selective Tumor Suppression.
Pt(IV) prodrugs offer a versatile platform for the design of platinum-based antitumor drugs; yet utilizing axial ligands to actively modulate tumor bioenergetics has been less investigated. Herein, we report a mitochondria-directed Pt(IV) prodrug, LA-Pt(IV), in which lipoic acid (LA) serves as a metabolite-reactive axi...